LAPTM5通过调控小管衰老促进CKD进展
本研究探讨了溶酶体相关蛋白跨膜5(LAPTM5)在CKD小管衰老中的作用。通过多种小鼠CKD模型及小管特异性基因敲除,发现LAPTM5在肾小管上皮细胞中诱导表达,敲除后可减轻小管衰老和纤维化。机制上LAPTM5通过介导WWP2溶酶体降解抑制notch1胞内域泛素化,从而促进细胞衰老;CKD患者小管LAPTM5表达升高且与纤维化和衰老相关。
要点
- LAPTM5在CKD肾小管上皮细胞中表达显著增加。
- 小管特异性敲除Laptm5可减轻小鼠CKD纤维化和衰老。
- LAPTM5通过WWP2/notch1胞内域通路促进小管衰老。
核心结论
- LAPTM5通过调控WWP2/notch1胞内域信号通路促进小管衰老,并加剧CKD进展中的肾损伤。
研究设计与样本
- 使用Laptm5−/−小鼠和小管特异性Laptm5敲除小鼠,建立多种实验性小鼠CKD模型。
- 观察了马兜铃酸肾病、双侧缺血再灌注损伤诱导的CKD及单侧输尿管梗阻模型。
主要发现
- LAPTM5在CKD小鼠肾脏近端小管和远端小管中表达显著诱导。
- 小管特异性敲除Laptm5抑制衰老鼠小管上皮细胞衰老并减轻小管间质纤维化。
- Laptm5缺失改善CKD小鼠肾损伤和小管衰老。
- 机制上LAPTM5通过介导WWP2溶酶体降解抑制notch1胞内域泛素化,导致小管上皮细胞衰老。
- CKD患者小管LAPTM5表达升高,且与肾纤维化和小管衰老相关。
临床怎么用
- LAPTM5可能作为CKD小管衰老的潜在治疗靶点,但尚需临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Lysosomal-associated protein transmembrane 5 (LAPTM5) is increased in tubular epithelial cells in CKD. Conditional knockout of Laptm5 in tubules attenuates kidney fibrosis in mice with CKD. LAPTM5 contributes to tubular senescence by inhibiting WWP2-mediated ubiquitination of notch1 intracellular domain. BACKGROUND: Tubular senescence is a major determinant of CKD, and identification of potential therapeutic targets involved in senescent tubular epithelial cells has clinical importance. Lysosomal-associated protein transmembrane 5 (LAPTM5) is a key molecule related to T- and B-cell receptor expression and inflammation. However, the expression pattern of LAPTM5 in the kidney and the contribution of LAPTM5 to the development of CKD are unknown. METHODS: Laptm5−/− mice and tubule specific–Laptm5 knockout mice were used to examine the role of LAPTM5 in tubular senescence by establishing different experimental mouse CKD models. RESULTS: LAPTM5 expression was significantly induced in the kidney, especially in proximal tubules and distal convoluted tubules, from mice with aristolochic acid nephropathy, bilateral ischemia/reperfusion injury–induced CKD, or unilateral ureter obstruction. Tubule-specific deletion of Laptm5 inhibited senescence of tubular epithelial cells and alleviated tubulointerstitial fibrosis in aged mice. Moreover, Laptm5 deficiency ameliorated kidney injury and tubular senescence in mice with CKD. Mechanistically, LAPTM5 inhibited ubiquitination of notch1 intracellular domain by mediating WWP2 lysosomal degradation and then leading to cellular senescence in tubular epithelial cells. We also observed a higher expression of LAPTM5 in tubules from patients with CKD, and the level of LAPTM5 was correlated with kidney fibrosis and tubular senescence in people with CKD. CONCLUSIONS: LAPTM5 contributed to tubular senescence by regulating the WWP2/notch1 intracellular domain signaling pathway and exacerbated kidney injury during the progression of CKD.
引用
- Liu X, Zhan P, Zhang Y, et al. Lysosomal-Associated Protein Transmembrane 5, Tubular Senescence, and Progression of CKD. J Am Soc Nephrol. 2024. PMID: 39078711. doi:10.1681/ASN.0000000000000446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。